Motavizumab, palivizumab
MI-CP127
Phase 2 mab completed
Quick answer
Motavizumab, palivizumab for Respiratory Syncytial Virus Infections is a Phase 2 program (mab) at MedImmune with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MedImmune
- Indication
- Respiratory Syncytial Virus Infections
- Phase
- Phase 2
- Modality
- mab
- Status
- completed